NCT01943396

Treatment of AMD With Rheohemapheresis /RHF/

Rationalization of the Systemic Treatment of Age-related Macular Degeneration With Rheohemapheresis (RHF)

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: University Hospital Hradec Kralove · Academic / Other
• Sex: All
• Age: 85 Years
• Healthy volunteers: Not accepted

Summary

In this research rheohemapheresis will be used for the treatment of patients with high-risk dry form of age-related macular degeneration. Correction of rheologic parameters and activation of retinal functional reserves after the therapy will positively influence functional condition of retina. The newest special electrophysiologic methods will be used to determine retinal changes in time. The investigators will also evaluate some important immunologic factors and complement changes as well as define indication criteria more precisely.

Detailed description

With optimized therapeutic protocol we would prevent progression of the dry form of AMD into its devastating wet form and stabilize the situation. We suppose that retinal morphologic and functional conditions would improve in a high percentage of patients. Also possible technical and economic savings would not be less important with our own therapeutic protocol, especially, when blindness could be prevented.

Conditions

• Age Related Macular Degeneration

Interventions

Type	Name	Description
PROCEDURE	rheohemapheresis	Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.

Timeline

• Start date: 2013-09-01
• Primary completion: 2016-05-01
• Completion: 2016-09-01
• First posted: 2013-09-17
• Last updated: 2016-06-01

Locations

1 site across 1 country: Czechia